NCT01661283

SARC016: Study of Everolimus With Bevacizumab to Treat Refractory Malignant Peripheral Nerve Sheath Tumors

Phase 2 Study of the mTOR Inhibitor Everolimus in Combination With Bevacizumab in Patients With Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 25 (actual)
• Sponsor: Sarcoma Alliance for Research through Collaboration · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To determine the clinical response rate of everolimus in combination with bevacizumab for patients with chemotherapy refractory sporadic or neurofibromatosis type 1 (NF1) associated malignant peripheral nerve sheath tumor (MPNST). To evaluate the toxicity and safety of everolimus in combination with bevacizumab in individuals with MPNST

Conditions

• Malignant Peripheral Nerve Sheath Tumors
• MPNST
• Sarcoma

Interventions

Type	Name	Description
DRUG	everolimus	10 mg tablet once daily
DRUG	bevacizumab	10 mg/kg dose every 14 days

Timeline

• Start date: 2012-09-01
• Primary completion: 2017-06-01
• Completion: 2017-12-01
• First posted: 2012-08-09
• Last updated: 2019-03-06
• Results posted: 2019-03-06

Locations

12 sites across 1 country: United States